Abstract
Altering the rate of translation initiation of a specific gene can tightly regulate the synthesis of the corresponding polypeptide and is an important mechanism in the control of gene expression. For some time it has been known that many genes involved in cell proliferation, cell growth and apoptosis have atypical 5 untranslated regions (UTRs) containing a high degree of RNA secondary structure, upstream open reading frames and internal ribosome entry segments. These features play a key role in the regulation of protein synthesis. In this review we discuss how the rate of translation initiation of proto-oncogenes and tumour suppressor genes is affected by elements in their 5 and 3 UTRs and we focus on how changes in the control of gene expression at this level can contribute towards tumorigenesis.
Keywords: protein synthesis, translation, tumorigenesis, untranslated region
Current Molecular Medicine
Title: Aberrant Regulation of Translation Initiation in Tumorigenesis
Volume: 3 Issue: 7
Author(s): Mark Stoneley and Anne E. Willis
Affiliation:
Keywords: protein synthesis, translation, tumorigenesis, untranslated region
Abstract: Altering the rate of translation initiation of a specific gene can tightly regulate the synthesis of the corresponding polypeptide and is an important mechanism in the control of gene expression. For some time it has been known that many genes involved in cell proliferation, cell growth and apoptosis have atypical 5 untranslated regions (UTRs) containing a high degree of RNA secondary structure, upstream open reading frames and internal ribosome entry segments. These features play a key role in the regulation of protein synthesis. In this review we discuss how the rate of translation initiation of proto-oncogenes and tumour suppressor genes is affected by elements in their 5 and 3 UTRs and we focus on how changes in the control of gene expression at this level can contribute towards tumorigenesis.
Export Options
About this article
Cite this article as:
Stoneley Mark and Willis E. Anne, Aberrant Regulation of Translation Initiation in Tumorigenesis, Current Molecular Medicine 2003; 3 (7) . https://dx.doi.org/10.2174/1566524033479474
DOI https://dx.doi.org/10.2174/1566524033479474 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances in the Development of Catalytic Inhibitors of Human DNA Topoisomerase IIα As Novel Anticancer Agents
Current Medicinal Chemistry Deregulation of Apoptosis - Is it Still an Important Issue in Pathogenesis of Chronic Lymphocytic Leukemia?
Current Cancer Drug Targets Electrochemical Indicators for DNA Electroanalysis
Current Analytical Chemistry Global Gene Expression in Classification, Pathogenetic Understanding and Identification of Therapeutic Targets in Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology Cell Type Specific Redox Status is Responsible for Diverse Electromagnetic Field Effects
Current Medicinal Chemistry Can γH2AX be Used to Personalise Cancer Treatment?
Current Molecular Medicine Life and Death of Leukemic Cells Under Bcr-Abl Signaling Control
Current Cancer Therapy Reviews Anti-Inflammatory Agents from Plants: Progress and Potential
Current Medicinal Chemistry Evaluating Treatment Response of Chronic Myeloid Leukemia: Emerging Science and Technology
Current Cancer Drug Targets 3-Hydroxy-2-phenyl-4(1H)-quinolinones as Promising Biologically Active Compounds
Mini-Reviews in Medicinal Chemistry MiRNAs in Human Cancers: The Diagnostic and Therapeutic Implications
Current Pharmaceutical Design Cancer Stem Cells in Solid and Liquid Tissues of Breast Cancer Patients: Characterization and Therapeutic Perspectives
Current Cancer Drug Targets The Anticancer Face of Interferon Alpha (IFN-Alpha): From Biology to Clinical Results, with a Focus on Melanoma
Current Medicinal Chemistry Rho-Signaling Pathways in Chronic Myelogenous Leukemia
Cardiovascular & Hematological Disorders-Drug Targets Stem Cell Transplantation in Pediatric Leukemia and Myelodysplasia: State of the Art and Current Challenges
Current Stem Cell Research & Therapy Cytokines as Novel Therapeutic Agents for Neuroinflammatory Disorders: A Role for Interferon-β in the Treatment of Multiple Sclerosis
Current Medicinal Chemistry - Central Nervous System Agents Power from the Garden: Plant Compounds as Inhibitors of the Hallmarks of Cancer
Current Medicinal Chemistry Is There a Clinical Future for Spermatogonial Stem Cells?
Current Stem Cell Research & Therapy Performance of Feature Selection Methods
Current Genomics Inhibitors of Cyclin Dependent Kinases: Useful Targets for Cancer Treatment
Current Cancer Drug Targets